Tofacitinib - Pfizer

Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690-550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis; Ulcerative colitis
  • Registered Psoriatic arthritis
  • Phase III Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis
  • Phase II Atopic dermatitis
  • Phase I/II Diffuse scleroderma
  • Phase I Dermatomyositis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 01 Aug 2018 Registered for Ulcerative colitis in Liechtenstein, Iceland, Norway, and European Union (PO)
  • 28 Jun 2018 Registered for Psoriatic arthritis (Combination therapy, Treatment-experienced, Treatment resistant) in Liechtenstein, Iceland, Norway, European Union (PO)
  • 13 Jun 2018 Pooled safety data from phase III trials in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top